Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
66 hedge funds and large institutions have $16.2M invested in Zynerba Pharmaceuticals, Inc in 2020 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 13 increasing their positions, 29 reducing their positions, and 21 closing their positions.
13% more call options, than puts
Call options by funds: $1.4M | Put options by funds: $1.24M
11% less funds holding
Funds holding: 74 → 66 (-8)
37% less capital invested
Capital invested by funds: $25.6M → $16.2M (-$9.38M)
38% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 21
55% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$200K |
| 2 |
Walleye Capital
New York
|
+$189K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$176K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$152K |
| 5 |
JWCA
J.W. Cole Advisors
Tampa,
Florida
|
+$136K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.18M |
| 2 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
-$1.44M |
| 3 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$1.29M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$559K |
| 5 |
Jane Street
New York
|
-$466K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
76
Tower Research Capital (TRC)
New York
| – | -$21K | -6,213 | Closed |
|
|
SFS
77
Sowell Financial Services
North Little Rock,
Arkansas
| – | -$8.39K | -2,283 | -97% |
|
|
PCM
78
Prelude Capital Management
New York
| – | -$6K | -1,769 | Closed |
|
|
CL
79
CSS LLC
Chicago,
Illinois
| – | -$4K | -1,200 | Closed |
|
80
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$3K | -967 | Closed |
|
|
APA
81
American Portfolios Advisors
Holbrook,
New York
| – | -$1.44K | -428 | Closed |
|
|
PAG
82
Private Advisor Group
Morristown,
New Jersey
| – | -$1K | -291 | Closed |
|
83
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$1K | -200 | Closed |
|
ZYNE Hedge Fund Activity: Q3 2020 in Review
66 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q3 2020, worth a combined $16.2M — down 37% from $25.6M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ZYNE and 13 opened new positions — a net loss of 8 holders — while 29 trimmed existing stakes and 13 added.
The largest buyer was Mirae Asset Global Investments, adding an estimated $200K. The largest seller was Ikarian Capital, exiting entirely with an estimated $2.18M sold.
- 66 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q3 2020, down from 74 in Q2 2020.
- Funds reported $16.2M of Zynerba Pharmaceuticals, Inc stock for Q3 2020, down 37% quarter-over-quarter.
- 13 funds opened new Zynerba Pharmaceuticals, Inc positions in Q3 2020 and 21 closed out, a net change of -8 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q3 2020 was Mirae Asset Global Investments, an estimated $200K added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q3 2020 was Ikarian Capital, an estimated $2.18M sold.
Based on aggregated 13F filings for Q3 2020.